Hepatitis E vaccine

Hepatitis E Vaccine is a vaccine that provides immunity against the Hepatitis E virus (HEV). The vaccine is primarily used in areas where the virus is endemic, and in populations at high risk of infection.

Overview[edit | edit source]

The Hepatitis E vaccine is a recombinant vaccine. It is produced by inserting a piece of the virus's genetic material into a harmless bacterium or yeast, which then produces an antigen that stimulates the immune system. The vaccine is administered in three doses over a six-month period.

Efficacy[edit | edit source]

Clinical trials have shown that the Hepatitis E vaccine is highly effective in preventing Hepatitis E infection. A study published in the New England Journal of Medicine found that the vaccine had an efficacy rate of 95.5% in a population at high risk of infection.

Availability[edit | edit source]

The Hepatitis E vaccine is currently available in China, where it was approved for use in 2012. It is not yet approved for use in other countries, although it is under review by the World Health Organization (WHO).

Safety[edit | edit source]

The Hepatitis E vaccine has a good safety profile. The most common side effects are mild and include pain at the injection site and mild fever. Serious side effects are rare.